Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.
3.

Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men.

Beer NA, Jakubowicz DJ, Beer RM, Arocha IR, Nestler JE.

J Clin Endocrinol Metab. 1993 Jan;76(1):178-83.

PMID:
8421087
4.

Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese hypertensive men and women.

Beer NA, Jakubowicz DJ, Beer RM, Nestler JE.

J Clin Endocrinol Metab. 1994 Oct;79(4):1077-81.

PMID:
7962276
5.

Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men.

Nestler JE, Beer NA, Jakubowicz DJ, Beer RM.

J Clin Endocrinol Metab. 1994 Mar;78(3):549-54.

PMID:
8126125
6.

The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women.

Mortola JF, Yen SS.

J Clin Endocrinol Metab. 1990 Sep;71(3):696-704.

PMID:
2144295
8.

Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity.

Ueshiba H, Tsuboi K, Miyachi Y.

Horm Metab Res. 2001 Mar;33(3):167-9.

PMID:
11355751
9.
10.

Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men.

Nestler JE, Barlascini CO, Clore JN, Blackard WG.

J Clin Endocrinol Metab. 1988 Jan;66(1):57-61.

PMID:
2961787
11.

Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients.

Bianchi R, Bongers V, Bravenboer B, Erkelens DW.

Diabetes Metab Rev. 1993 Nov;9 Suppl 1:29S-34S.

PMID:
8299486
12.

Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women.

Jakubowicz DJ, Beer NA, Beer RM, Nestler JE.

J Clin Endocrinol Metab. 1995 Nov;80(11):3373-6.

PMID:
7593454
13.

Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.

Morales AJ, Nolan JJ, Nelson JC, Yen SS.

J Clin Endocrinol Metab. 1994 Jun;78(6):1360-7. Erratum in: J Clin Endocrinol Metab 1995 Sep;80(9):2799.

PMID:
7515387
14.

Therapeutic effect of benfluorex in type II diabetic patients on diet regimen alone.

Velussi M, Monte AD, Cernigoi AM.

J Diabetes Complications. 1996 Sep-Oct;10(5):261-6.

PMID:
8887014
15.

Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women.

Basu R, Dalla Man C, Campioni M, Basu A, Nair KS, Jensen MD, Khosla S, Klee G, Toffolo G, Cobelli C, Rizza RA.

Diabetes. 2007 Mar;56(3):753-66. Erratum in: Diabetes. 2007 May;56(5):1486.

16.

Effect of a two-month detraining on glucose tolerance and insulin sensitivity in athletes--link to adrenal steroid hormones.

Wang PT, Chiang IT, Lin CY, Hou CW, Chen CY, Lee HH, Chang WH, Kuo CH.

Chin J Physiol. 2006 Oct 31;49(5):251-7.

PMID:
17294833
18.

Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men.

Beer NA, Jakubowicz DJ, Matt DW, Beer RM, Nestler JE.

Am J Med Sci. 1996 May;311(5):205-10.

PMID:
8615394
19.

Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.

Pontiroli AE, Pacchioni M, Piatti PM, Cassisa C, Camisasca R, Pozza G.

J Clin Endocrinol Metab. 1996 Oct;81(10):3727-32.

PMID:
8855830
20.

Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms.

Nestler JE, Usiskin KS, Barlascini CO, Welty DF, Clore JN, Blackard WG.

J Clin Endocrinol Metab. 1989 Nov;69(5):1040-6.

PMID:
2529264

Supplemental Content

Support Center